A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 = 50%. (ROSETTA Lung-202)

Active:	Yes
Cancer Type:	Lung Cancer	NCT ID:	NCT07361510
Trial Phases:	Phase III	Protocol IDs:	CA266-0002 (primary) 2025-523586-18 ( Other Identifier ) (OTHER: EU CT U1111-1326-9286 ( Other Identifier ) (OTHER: UTN)
Eligibility:	, Male and Female	Study Type:	Treatment
Study Sponsor:	Bristol-Myers Squibb
NCI Full Details:	https://clinicaltrials.gov/study/NCT07361510

Summary

The purpose of this study is to evaluate the efficacy of Pumitamig versus Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%.

Treatment Sites in Georgia

University Cancer and Blood Center, LLC - Athens Medical Oncology
3320 Old Jefferson Road
Building 800
Athens, GA 30607
www.universitycancer.com

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.